+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis



Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis



Respirology Case Reports 6(8): E00363



A 76-year-old man with a past history of acute exacerbation (AE) and idiopathic pulmonary fibrosis (IPF) was treated with nintedanib because of decline in his forced vital capacity over time. A new small nodular lesion was visible on a computed tomography scan of the chest before initiation of nintedanib. Disease progression in IPF and change in size of the nodular lesion were not detected during administration of nintedanib. Nine months after starting nintedanib, the patient was diagnosed with acute gangrenous appendicitis, and nintedanib treatment was discontinued. The nodular lesion increased in size four months after the cessation of nintedanib. The nodular lesion was diagnosed as squamous cell carcinoma. In this case, nintedanib inhibited the disease progression of IPF and lung cancer simultaneously. Nintedanib may play an important role in the treatment of IPF-associated lung cancer.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065858962

Download citation: RISBibTeXText

PMID: 30237884

DOI: 10.1002/rcr2.363


Related references

Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis. Cancer ChemoTherapy and Pharmacology 81(1): 89-101, 2017

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 72(4): 340-346, 2016

Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis. Clinical Lung Cancer 19(1): E5-E9, 2017

Progression of native lung fibrosis in lung transplant recipients with idiopathic pulmonary fibrosis. Respiratory Medicine 104(3): 426-433, 2010

Suspected accelerated disease progression after discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: Two case reports. Medicine 96(49): E9081, 2018

Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis. Respiratory Medicine 146: 42-48, 2019

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib. Drug Design, Development and Therapy 7: 503-510, 2013

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis, Cytisine versus Nicotine for Smoking Cessation, and FACED Score for Non-Cystic Fibrosis Bronchiectasis. American Journal of Respiratory and Critical Care Medicine 192(2): 249-251, 2015

Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respiratory Research 15: 157, 2015

Can Progression of Fibrosis as Assessed by Computer-Aided Lung Informatics for Pathology Evaluation and Rating (CALIPER) Predict Outcomes in Patients With Idiopathic Pulmonary Fibrosis?. Chest Journal 140(4): 1041a-1041b, 2011

Alteration of p53 gene in lung cancer and pulmonary fibrosis-related epithelial lesions in patients with idiopathic pulmonary fibrosis. Proceedings of the American Association for Cancer Research Annual Meeting (41): 295-296, 2000

Lung Cancer in Patients With Combined Pulmonary Fibrosis and Emphysema and Idiopathic Pulmonary Fibrosis. A Descriptive Study in a Spanish Series. Archivos de Bronconeumologia 53(6): 304-310, 2016

Epidermal growth factor receptor (EGFR) paracrine upregulation in idiopathic pulmonary fibrosis (IPF) fibroblasts is blocked by nintedanib. American Journal of Physiology. Lung Cellular and Molecular Physiology 2019, 2019

Nintedanib in idiopathic pulmonary fibrosis. Drugs of Today 51(6): 345-356, 2015

Nintedanib for Idiopathic Pulmonary Fibrosis. Journal of Pharmacy Practice 2017: 897190017735242, 2017